USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
STEMINA BIOMARKER DISCOVERY, INC.
Address:
504 S. Rosa Road
MADISON, WI 53719-1256
Phone:
(608) 204-0104
URL:
N/A
EIN:
208294201
DUNS:
794516695
Number of Employees:
11
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $445,449.00 3
SBIR Phase II $1,499,936.00 2

Award List:

SBIR TOPIC 245 "PREDICTIVE EFFICACY SCREENING IN CANCER STEM CELLS USING METABOLO

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$149,528.00
Agency:
HHS
Principal Investigator:
Paul West
Abstract:
Cancer stem cells (CSCs) are a critical tumor subpopulation that may cause local recurrences that plague patients with advanced solid malignancies, even after maximal therapeutic efforts. CSCs can self-renew, differentiate into multiple lineages, resist ra diation and chemotherapy, and efficiently… More

SBIR Phase I: Metabolomics of Human Embryonic Stem Cells to Predict Teratogenicity: An Alternative Developmental Toxicity Model

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$149,255.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I project proposes to develop a highly predictive model for assessing the potential of compounds to cause birth defects in the developing human embryo using human embryonic stem (hES) cells as the test substrate. The project proposes to use hES… More

Not Available

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$999,936.00
Agency:
HHS
Principal Investigator:
Paul West
Abstract:
Brain tumor stem cells (BTSCs) are a subset population within tumors that are widely believed to be  responsible for tumor recurrence, due to their ability to self-renew, differentiate, migrate, and initiate tumor  propagation. Given these unique features, the selective targeting of BTSCs… More

SBIR Phase II: Metabolomics of Human Embryonic Stem Cells to Predict Teratogenicity: An Alternative Developmental Toxicity Model

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II project will fund a continuation of breakthrough research, development and commercialization of an in vitro assay to help prevent birth defects. This innovative product is driven by a need to create a test for human developmental toxicity that… More

Identification of Biomarkers of Cardiotoxicity using Metabolomics of Human Plurip

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$146,666.00
Agency:
HHS
Principal Investigator:
Robert E. Burrier – 608-204-0104
Abstract:
DESCRIPTION (provided by applicant): Cardiotoxicity, as a result of adverse drug effects, is a serious problem that has yet to be effectively screened prior to patient exposure. Cardiac safety is one of the leading causes of compound attrition in the pharmaceutical industry and withdrawal of… More